We are monitoring the impact of COVID-19 on North America CAR T cell Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2021
ID: 9966
Share on
Share on

North America CAR T cell Therapy Market Research Report - By Target Antigen, Products, Application, Country (the United States, Canada and Rest of North America) – Industry Size, Share, Trends and Forecast (2021 to 2026)

Pulished: August, 2021
ID: 9966
Pages: 100

North America CAR T cell Therapy Market Size (2021 to 2026)

The size of the CAR T cell Therapy Market in North America is estimated to grow at a remarkable CAGR of 62% from 2021 to 2026.

Factors like rising elder people population, an increasing number of cancer cases in children, and adults are majorly driving the CAR T cell therapy market growth in North America. Favorable government policies and also the initiatives taken to motivate the on-going research to treat cancer is to boost the market growth during the forecast period. An increasing number of clinical trials and advancements in technologies for reliable and effective cancer treatment is likely to spur the growth of the North American CAR T Cell therapy market growth throughout the forecast period.

Side effects associated with the CAR T cell Therapies are leading to cytokine release syndrome (CRS) is significantly limiting the market growth. Lack of awareness and the shortage of lab technicians among the hospitals and clinics, the absence of skilled professionals during the treatment of cell therapy, and cost-related issues are restraining the CAT T Cell therapy market growth over the analysis period.

This research report on the North American CAR T Cell therapy market has been segmented and sub-segmented into the following categories.

  • By Target Antigen: CD20, EGFRV III, CD19, HER2, MESO, CD22, BCMA, GD2, CD30, HER1, and CD33
  • By Application: Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse large B-cell lymphoma, and Acute Lymphoblastic Leukemia
  • By Product: Allogeneic and Autologous
  • By Therapies: Axicabtagene ciloleucel (Yescarta) and Tisagenlecleucel (Kymriah)
  • By End User: Cancer Research Centers, Hospitals, Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations
  • By Country: The United States, Canada and Rest of North America

Regional Analysis:

North America is expected to continue its dominance in the domain CAR T Cell therapy market during the forecast period. Factors like favorable government reimbursement policies, easy and early accessibility of CAR T Cell therapy influencing the market growth.

In North America, the U.S. is expected to lead the North American CAR T Cell therapy market and is estimated to dominate throughout the forecast period. R&D in the cell therapy area, continuous regular approvals for the products, and the novel drugs associated are causing the market growth in the United States.

Canada is anticipated to have a fast and fastest growth in the forthcoming years, followed by the United States. Escalating expenditure on healthcare, especially in urban areas, is fuelling the growth rate of the market. Rising population and creating awareness through digital advertisements are prompting the growth rate of the market in this country. 

Notable companies dominating the North American CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. OVERVIEW
    1. Executive Summary
    2. Key Inferences
  4. DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. MARKET SEGMENTATION
    1. By Target Antigen
      1. CD20
      2. EGFRV III
      3. CD19
      4. HER2
      5. MESO
      6. CD22
      7. BCMA
      8. GD2
      9. CD30
      10. HER1
      11. CD33
      12. Y-o-Y Growth Analysis, By Target Antigen
      13. Market Attractiveness Analysis, By Target Antigen
      14. Market Share Analysis, By Target Antigen
    2. By Application
      1. Multiple Myeloma
      2. Chronic Lymphocytic Leukemia
      3. Mantle Cell Lymphoma
      4. Follicular Lymphoma
      5. Diffuse large B-cell lymphoma
      6. Acute Lymphoblastic Leukemia
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
    3. By Product
      1. Allogeneic
      2. Autologous
      3. Y-o-Y Growth Analysis, By Product
      4. Market Attractiveness Analysis, By Product
      5. Market Share Analysis, By Product
    4. By Therapies
      1. Axicabtagene ciloleucel (Yescarta)
      2. Tisagenlecleucel (Kymriah)
      3. Y-o-Y Growth Analysis, By Therapies
      4. Market Attractiveness Analysis, By Therapies
      5. Market Share Analysis, By Therapies
    5. By End User
      1. Cancer Research Centers
      2. Hospitals
      3. Academic and Research Institutes
      4. Pharmaceutical Companies
      5. Biotechnology Companies
      6. Contract Research Organizations
      7. Y-o-Y Growth Analysis, By End User
      8. Market Attractiveness Analysis, By End User
  6. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. North America
      1. Introduction
      2. United States
      3. Canada
      4. Rest of North America
  7. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. MARKET LEADERS' ANALYSIS
    1. Mustang Bio, Inc.,
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Celgene Corporation
    3. Bluebird Bio, Inc.
    4. CARsgen Therapeutics, Ltd.
    5. Novartis International AG
    6. Legend Biotech
    7. Sorrento Therapeutics Inc.
    8. Kite Pharma, Inc.
    9. Immune Therapeutics
    10. Bellicum Pharmaceuticals, Inc.
    11. Pfizer, Inc.
  9. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  10. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  11. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is booming, and to also identify the areas that are still untapped.
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, vital financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Global CAR T cell Therapy Market, By Target Antigen, From 2021 to 2026 (USD Million)
  2. North America CD 20 Market, By Region, From 2021 to 2026 (USD Million)
  3. North America EGFRV III Market, By Region, From 2021 to 2026 (USD Million)
  4. North America CD 19 Market, By Region, From 2021 to 2026 (USD Million)
  5. North America HER 2 Market, By Region, From 2021 to 2026 (USD Million)
  6. North America MESO Market, By Region, From 2021 to 2026 (USD Million)
  7. North America CD 22 Market, By Region, From 2021 to 2026 (USD Million)
  8. North America BCMA Market, By Region, From 2021 to 2026 (USD Million)
  9. North America GD 2 Market, By Region, From 2021 to 2026 (USD Million)
  10. North America CD 30 Market, By Region, From 2021 to 2026 (USD Million)
  11. North America HER 1 Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Global CAR T cell Therapy Market, By Application, From 2021 to 2026 (USD Million)
  13. North America Multiple Myeloma Market, By Region, From 2021 to 2026 (USD Million)
  14. North America Chronic Lymphocytic Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Mantle Cell Lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Follicular Lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  17. North America Diffuse large B-cell Lymphoma Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Acute Lymphoblastic Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Global CAR T cell Therapy Market, By Product, From 2021 to 2026 (USD Million)
  20. North America Allogeneic Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Autologous Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Global CAR T cell Therapy Market, By Therapies, From 2021 to 2026 (USD Million)
  23. North America Axicabtagene Ciloleucel (Yescarta) Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Tisagenlecleucel (Kymriah) Market, By Region, From 2021 to 2026 (USD Million)
  25. North America Global CAR T cell Therapy Market, By End-User, From 2021 to 2026 (USD Million)
  26. North America Cancer Reasearch Centers Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Academic and Research institutes Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Pharmaceutical Companies Market, By Region, From 2021 to 2026 (USD Million)
  30. North America Biotechnology Companies  Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Contract Research Organizations Market, By Region, From 2021 to 2026 (USD Million)
  32. United States Global CAR T cell Therapy Market, By Target Antigen, From 2021 to 2026 (USD Million)
  33. United States Global CAR T cell Therapy Market, By Application, From 2021 to 2026 (USD Million)
  34. United States Global CAR T cell Therapy Market, By Product, From 2021 to 2026 (USD Million)
  35. United States Global CAR T cell Therapy Market, By Therapies, From 2021 to 2026 (USD Million)
  36. United States Global CAR T cell Therapy Market, By End-User, From 2021 to 2026 (USD Million)
  37. Canada Global CAR T cell Therapy Market, By Target Antigen, From 2021 to 2026 (USD Million)
  38. Canada Global CAR T cell Therapy Market, By Application, From 2021 to 2026 (USD Million)
  39. Canada Global CAR T cell Therapy Market, By Product, From 2021 to 2026 (USD Million)
  40. Canada Global CAR T cell Therapy Market, By Therapies, From 2021 to 2026 (USD Million)
  41. Canada Global CAR T cell Therapy Market, By End-User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample